Urology Search
Urology Urology
benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.

Benign Prostatic Hyperplasia Drug Information

Drug Information

Indication: Functional symptoms of benign prostatic hyperplasia (BPH).

Indication: HTN. Symptomatic relief of benign prostatic hyperplasia (BPH).

Indication: Bladder outlet obstruction associated w/ BPH in patients ≥50 yr.

Indication: Monotherapy or in combination w/ tamsulosin for treatment & control of symptomatic benign prostatic hyperp...

Indication: HTN & initial agent to control BP. In hypertensive or normotensive patients w/ benign prostatic hyperplasi...

Indication: Erectile dysfunction. 5 mg: Symptomatic treatment of benign prostatic hyperplasia (BPH).

Indication: Symptomatic benign prostatic hyperplasia (BPH). HTN.

Indication: Moderate to severe benign prostatic hyperplasia (BPH) symptoms; reduces risk of acute urinary retention & ...

Indication: HTN. Improve clinical symptoms & increase urine flow in benign prostatic hyperplasia.

Indication: HTN & benign prostatic hyperplasia (BPH).

1  /  2
1  /  2
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Standing good for heart health
Jairia Dela Cruz, 23 hours ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Early life exposure helps ward off later allergies to cow’s milk formula
5 days ago
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.